0001104659-17-041901.txt : 20170627
0001104659-17-041901.hdr.sgml : 20170627
20170627215451
ACCESSION NUMBER: 0001104659-17-041901
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170623
FILED AS OF DATE: 20170627
DATE AS OF CHANGE: 20170627
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Nabriva Therapeutics Plc
CENTRAL INDEX KEY: 0001703287
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L2
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 56 FITZWILLIAM SQUARE
CITY: DUBLIN
STATE: L2
ZIP: 2
BUSINESS PHONE: 6108166640
MAIL ADDRESS:
STREET 1: 1000 CONTINENTAL DRIVE
STREET 2: SUITE 600
CITY: KING OF PRUSSIA
STATE: PA
ZIP: 19406
FORMER COMPANY:
FORMER CONFORMED NAME: Nabriva Plc
DATE OF NAME CHANGE: 20170407
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Talbot George Harrison
CENTRAL INDEX KEY: 0001554194
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38132
FILM NUMBER: 17933628
MAIL ADDRESS:
STREET 1: C/O DURATA THERAPEUTICS, INC.
STREET 2: 89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR
CITY: MORRISTOWN
STATE: NJ
ZIP: 07960
4
1
a4.xml
4
X0306
4
2017-06-23
0
0001703287
Nabriva Therapeutics Plc
NBRV
0001554194
Talbot George Harrison
1000 CONTINENTAL DRIVE
SUITE 600
KING OF PRUSSIA
PA
19406
1
0
0
0
Ordinary Shares
2017-06-23
5
J
0
E
31790
0
A
31790
D
Stock Option
2017-06-23
5
J
0
E
40000
0
A
2025-07-05
Ordinary Shares
40000
40000
D
Stock Option
2017-06-23
5
J
0
E
10100
0
A
2026-08-25
Ordinary Shares
10100
10100
D
Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG. The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc.
This option was granted on July 6, 2015. Vesting began on July 31, 2015 and ends on July 31, 2019. Twenty-five percent (25%) of the option vested on July 31, 2016, and the remaining seventy-five percent (75%) vests on a monthly pro-rata basis over the remaining vesting period.
The exercise price is 6.618 Euro.
This option was granted on August 26, 2016. Vesting began on August 31, 2016 and ends on August 31, 2017. One hundred percent (100%) of the option will vest on August 31, 2017.
The exercise price is 6.634 Euro.
/s/ George Harrison Talbot
2017-06-27